famotidine + celecoxib

A combination of **famotidine** (a histamine H2 receptor antagonist) and **celecoxib** (a selective COX-2 inhibitor), developed as an experimental therapy primarily for critically ill COVID-19 patients. The rationale combines famotidine’s anti-histaminic and potential anti-inflammatory properties with celecoxib’s inhibition of inflammation through COX-2 blockade. In clinical evaluation (notably in the I-SPY COVID Trial), this combination was tested for the potential to reduce inflammation and virus-related complications but failed to demonstrate clinical benefit and may have been associated with increased risk in critically ill populations[1][2][3][4]. The combination is not an established or approved treatment for COVID-19 or any other indication, and there is no marketed brand/formulation containing both agents.

Other names

famotidine + celecoxibcelecoxib and famotidine combination